Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACH
ACH logo

ACH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.935
Open
3.730
VWAP
3.77
Vol
664.65K
Mkt Cap
283.58M
Low
3.670
Amount
2.51M
EV/EBITDA(TTM)
5.38
Total Shares
76.44M
EV
2.05B
EV/OCF(TTM)
13.28
P/S(TTM)
0.10
Accendra Health, Inc., formerly Owens & Minor, Inc., is a nationwide pure play home-based care platform. Its Patient Direct segment includes home healthcare divisions (Byram and Apria). The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery, including diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services). Additionally, it supplies a wide range of other home medical equipment, patient care product lines including ostomy, wound care (including negative pressure wound therapy), urology, incontinence and other products and services.
Show More

Events Timeline

(ET)
2026-02-19
16:20:00
Sees FY26 Adjusted EBITDA of $335M-$355M
select
2026-02-19
16:20:00
Accendra Health Q4 Revenue at $709M
select

News

Newsfilter
9.5
05-01Newsfilter
Accendra Health to Release Q1 2026 Financial Results
  • Earnings Release Schedule: Accendra Health plans to release its Q1 2026 financial results on May 11, 2026, before the market opens on the NYSE, reflecting the company's ongoing growth in health management.
  • Investor Conference Call: The company will host a conference call for investors and analysts at 8:30 a.m. EDT on the same day, allowing participants to engage through the toll-free dial-in number 1-888-300-2035, enhancing investor relations.
  • Live Webcast Access: Interested stakeholders can access the live webcast by visiting Accendra Health's Investor Relations page, promoting transparency and information sharing during the earnings announcement.
  • Company Overview: Accendra Health is a leading nationwide provider of health products and services, focused on improving the quality of life for patients with chronic conditions, showcasing its innovative capabilities and market leadership in home-based care.
Fool
8.5
02-05Fool
Medline's IPO Raises $6.3 Billion, Valuation Reaches $35.5 Billion
  • IPO Financing Scale: Medline's IPO successfully raised $6.3 billion at a price of $29 per share, significantly enhancing the company's capital structure, with plans to use the proceeds to pay down $16.5 billion in debt, thereby improving financial health.
  • Sales Growth Momentum: Since its founding in 1966, Medline has achieved an average annual sales growth of 18%, with projections indicating sales will reach $30 billion by 2026, demonstrating strong growth potential in the medical supply market, particularly given the resilience of healthcare demand amid economic uncertainties.
  • Market Competitive Advantage: With 335,000 products and 33 manufacturing facilities, Medline offers next-day delivery to 95% of U.S. customers, leveraging its private label products to enhance margins and solidify its leadership position in the medical product supply chain.
  • Superior Financial Performance: Medline boasts a gross margin of approximately 27.4%, significantly higher than key competitors, and is projected to generate $1.5 billion in free cash flow in 2025, showcasing its profitability and cash flow generation capabilities, further enhancing its investment appeal.
NASDAQ.COM
4.5
01-08NASDAQ.COM
NASDAQ 100 Pre-Market Indicator Falls, ACRV Trades Over 23 Million Shares
  • Market Dynamics: The NASDAQ 100 Pre-Market Indicator decreased by 4.3 points to 25,649.6, indicating weakened market sentiment that could impact investor confidence and lead to increased volatility in the short term.
  • ACRV Trading Activity: Acrivon Therapeutics, Inc. (ACRV) saw a pre-market trading volume of 23,307,591 shares, with a price drop of $0.06 to $2.89, reflecting high market interest but potential short-term pressure on the stock.
  • TSLA and TQQQ Performance: Direxion Daily TSLA Bull 2X Shares (TSLL) and ProShares UltraPro QQQ (TQQQ) fell by $0.27 and $0.17 respectively, despite TQQQ's 214.29% increase from its 52-week low, indicating ongoing market uncertainty.
  • VTYX and NVDA Recommendations: Ventyx Biosciences, Inc. (VTYX) and NVIDIA Corporation (NVDA) are both rated within the 'buy range', trading 2,195,689 shares and 2,158,778 shares respectively, demonstrating sustained investor interest in tech stocks.
Wall Street analysts forecast ACH stock price to rise
3 Analyst Rating
Wall Street analysts forecast ACH stock price to rise
1 Buy
1 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
2.50
Averages
3.50
High
4.00
Current: 0.000
sliders
Low
2.50
Averages
3.50
High
4.00
Citi
Buy
downgrade
$4
AI Analysis
2026-02-23
Reason
Citi
Price Target
$4
AI Analysis
2026-02-23
downgrade
Buy
Reason
Citi lowered the firm's price target on Accendra Health to $3.25 from $4 and keeps a Buy rating on the shares.
UBS
Kevin Caliendo
Buy
downgrade
$4 -> $3
2026-02-22
Reason
UBS
Kevin Caliendo
Price Target
$4 -> $3
2026-02-22
downgrade
Buy
Reason
UBS analyst Kevin Caliendo lowered the firm's price target on Accendra Health to $3 from $4 and keeps a Buy rating on the shares. The firm updated the company's model post the Q4 report.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACH
Unlock Now

Valuation Metrics

The current forward P/E ratio for Accendra Health Inc (ACH.N) is 2.86, compared to its 5-year average forward P/E of 3.09. For a more detailed relative valuation and DCF analysis to assess Accendra Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
3.09
Current PE
2.86
Overvalued PE
3.35
Undervalued PE
2.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.23
Current EV/EBITDA
7.90
Overvalued EV/EBITDA
11.10
Undervalued EV/EBITDA
7.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.07
Current PS
0.11
Overvalued PS
0.09
Undervalued PS
0.06

Financials

AI Analysis
Annual
Quarterly

Whales Holding ACH

C
Coliseum Capital Management, LLC
Holding
ACH
-4.95%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Accendra Health Inc (ACH) stock price today?

The current price of ACH is 3.71 USD — it has decreased -0.8

What is Accendra Health Inc (ACH)'s business?

Accendra Health, Inc., formerly Owens & Minor, Inc., is a nationwide pure play home-based care platform. Its Patient Direct segment includes home healthcare divisions (Byram and Apria). The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery, including diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services). Additionally, it supplies a wide range of other home medical equipment, patient care product lines including ostomy, wound care (including negative pressure wound therapy), urology, incontinence and other products and services.

What is the price predicton of ACH Stock?

Wall Street analysts forecast ACH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACH is3.50 USD with a low forecast of 2.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Accendra Health Inc (ACH)'s revenue for the last quarter?

Accendra Health Inc revenue for the last quarter amounts to 708.97M USD, increased 2.01

What is Accendra Health Inc (ACH)'s earnings per share (EPS) for the last quarter?

Accendra Health Inc. EPS for the last quarter amounts to -0.74 USD, decreased -80.78

How many employees does Accendra Health Inc (ACH). have?

Accendra Health Inc (ACH) has 6500 emplpoyees as of May 05 2026.

What is Accendra Health Inc (ACH) market cap?

Today ACH has the market capitalization of 283.58M USD.